Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2018 (2018), Article ID 1864307, 9 pages
https://doi.org/10.1155/2018/1864307
Research Article

Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway

Department of Endocrinology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, China

Correspondence should be addressed to Hong-Yu Kuang; moc.361@reimnefienydy

Received 7 September 2017; Revised 30 January 2018; Accepted 8 February 2018; Published 15 April 2018

Academic Editor: Niccola Funel

Copyright © 2018 Ning Shao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Tilg, A. R. Moschen, and M. Roden, “NAFLD and diabetes mellitus,” Nature Reviews Gastroenterology & Hepatology, vol. 14, no. 1, pp. 32–42, 2017. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Bril and K. Cusi, “Nonalcoholic fatty liver disease: the new complication of type 2 diabetes mellitus,” Endocrinology and Metabolism Clinics of North America, vol. 45, no. 4, pp. 765–781, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. J. D. Browning and J. D. Horton, “Molecular mediators of hepatic steatosis and liver injury,” The Journal of Clinical Investigation, vol. 114, no. 2, pp. 147–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Charytoniuk, K. Drygalski, K. Konstantynowicz-Nowicka, K. Berk, and A. Chabowski, “Alternative treatment methods attenuate the development of NAFLD: a review of resveratrol molecular mechanisms and clinical trials,” Nutrition, vol. 34, pp. 108–117, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. Z. Li, M. Berk, T. M. McIntyre, G. J. Gores, and A. E. Feldstein, “The lysosomal-mitochondrial axis in free fatty acid–induced hepatic lipotoxicity,” Hepatology, vol. 47, no. 5, pp. 1495–1503, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. C. P. Day and O. F. James, “Steatohepatitis: a tale of two “hits”?” Gastroenterology, vol. 114, no. 4, pp. 842–845, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Yilmaz, “Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?” Alimentary Pharmacology and Therapeutics, vol. 36, no. 9, pp. 815–823, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. G. Netea and J. W. van der Meer, “Immunodeficiency and genetic defects of pattern-recognition receptors,” The New England Journal of Medicine, vol. 364, no. 1, pp. 60–70, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Zhou, A. S. Yazdi, P. Menu, and J. Tschopp, “A role for mitochondria in NLRP3 inflammasome activation,” Nature, vol. 469, no. 7329, pp. 221–225, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Nakahira, J. A. Haspel, V. A. Rathinam et al., “Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome,” Nature Immunology, vol. 12, no. 3, pp. 222–230, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Csak, M. Ganz, J. Pespisa, K. Kodys, A. Dolganiuc, and G. Szabo, “Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells,” Hepatology, vol. 54, no. 1, pp. 133–144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Hui, A. Nourparvar, X. Zhao, and R. Perfetti, “Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5-adenosine monophosphate-dependent protein kinase A-and a phosphatidylinositol 3-kinase-dependent pathway,” Endocrinology, vol. 144, no. 4, pp. 1444–1455, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Bi, B. Zhang, W. Xu et al., “Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes,” Acta Diabetologica, vol. 51, no. 5, pp. 865–873, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Shao, H. Y. Kuang, M. Hao, X. Y. Gao, W. J. Lin, and W. Zou, “Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes,” Diabetes/Metabolism Research and Reviews, vol. 30, no. 6, pp. 521–529, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Birnbaum, M. Bajaj, J. Qian, and Y. Ye, “Dipeptidyl peptidase-4 inhibition by saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome,” vol. 4, no. 1, Article ID e000227, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Zhou, Y. Zhang, J. Chen, X. Hu, and Y. Xu, “Liraglutide attenuates lipopolysaccharide-induced acute lung injury in mice,” European Journal of Pharmacology, vol. 791, pp. 735–740, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. Q. He, S. Sha, L. Sun, J. Zhang, and M. Dong, “GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway,” Biochemical and Biophysical Research Communications, vol. 476, no. 4, pp. 196–203, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. S. W. Zhou, M. Zhang, and M. Zhu, “Liraglutide reduces lipid accumulation in steatotic L-02 cells by enhancing autophagy,” Molecular Medicine Reports, vol. 10, no. 5, pp. 2351–2357, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. K. H. Williams, N. A. Shackel, M. D. Gorrell, S. V. McLennan, and S. M. Twigg, “Diabetes and nonalcoholic fatty liver disease: a pathogenic duo,” Endocrine Reviews, vol. 34, no. 1, pp. 84–129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. Dai, D. Dai, X. Wang, Z. Ding, and J. L. Mehta, “DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway,” Cardiovascular Drugs and Therapy, vol. 28, no. 5, pp. 425–432, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Zou, J. Li, C. Lu et al., “High-fat emulsion-induced rat model of nonalcoholic steatohepatitis,” Life Sciences, vol. 79, no. 11, pp. 1100–1107, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. L. S. Mansor, E. R. Gonzalez, M. A. Cole et al., “Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin,” Cardiovascular Diabetology, vol. 12, no. 1, p. 136, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. D. J. Drucker, S. I. Sherman, F. S. Gorelick, R. M. Bergenstal, R. S. Sherwin, and J. B. Buse, “Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits,” Diabetes Care, vol. 33, no. 2, pp. 428–433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. N. A. Gupta, J. Mells, R. M. Dunham et al., “Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway,” Hepatology, vol. 51, no. 5, pp. 1584–1592, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Mima, J. Hiraoka-Yamomoto, Q. Li et al., “Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes,” Diabetes, vol. 61, no. 11, pp. 2967–2979, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Kwon, K. L. Pappan, C. A. Marshall, J. E. Schaffer, and M. L. McDaniel, “cAMP dose-dependently prevents palmitate-induced apoptosis by both protein kinase A- and Camp-guanine nucleotide exchange factor-dependent pathways in β-cells,” Journal of Biological Chemistry, vol. 279, no. 10, pp. 8938–8945, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. K. S. Boye, L. S. Matza, A. Oglesby et al., “Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes,” Health and Quality of Life Outcomes, vol. 4, no. 1, p. 80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. A. A. Tahrani, C. J. Bailey, S. Del Prato, and A. H. Barnett, “Management of type 2 diabetes: new and future developments in treatment,” The Lancet, vol. 378, no. 9786, pp. 182–197, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. K. He, X. Zhu, Y. Liu et al., “Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development,” Oncotarget, vol. 8, no. 23, pp. 37657–37672, 2017. View at Publisher · View at Google Scholar · View at Scopus
  30. M. J. Armstrong, D. Hull, K. Guo et al., “Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis,” Journal of Hepatology, vol. 64, no. 2, pp. 399–408, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Yamamoto, Y. Nakade, T. Yamauchi et al., “Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice,” World Journal of Gastroenterology, vol. 22, no. 8, pp. 2512–2523, 2016. View at Publisher · View at Google Scholar · View at Scopus